EMA Authorised: Afiveg (aflibercept) — STADA Arzneimittel AG

View source ↗

Summary

The EMA has authorised Afiveg, an aflibercept product by STADA, for multiple retinal conditions including wet age-related macular degeneration and diabetic macu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization
• Diabetic Macular Edema
• Macular Edema
• Retinal Vein Occlusion
• Wet Age-related Macular Degeneration

Drugs mentioned

• Afiveg (aflibercept)

Snippet

Status: Authorised. Therapeutic area: Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion;Choroidal Neovascularization. MAH: STADA Arzneimittel AG. Decision date: 18/08/2025